SLC35A2 and hepatocellular carcinoma: First, it was found that compared with non-cancer participants, UGT*1 was significantly decreased in cancer patient groups, especially in the HCC, CRC, and Asian population groups; UGT*2 was significantly increased in the HCC and Asian population groups; UGT*3 was significantly increased in the HCC, CRC, Caucasian, and Asian population groups.